Navigation Links
Prasco and Stiefel Sign Distribution and Supply Agreement for Clobetasol Propionate Foam
Date:12/22/2009

CINCINNATI, Dec. 22 /PRNewswire/ -- Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.

"We are pleased to provide pharmacists and consumers with the authorized generic of Olux® - a trusted brand product," said Prasco Chief Executive Officer E. Thomas Arington. "As a Prasco authorized generic, Clobetasol Propionate Foam will provide patients with the same quality and experience as the brand product," stated Arington. "We are especially pleased to expand our relationship with Stiefel and GSK, leaders in the pharmaceutical industry."

"Through our arrangement with Prasco, GlaxoSmithKline is able to expand patient access to our products by bringing brand quality to the generic marketplace," said Bill Humphries, President, Stiefel, a GSK company. "We are proud of our arrangement with Prasco, a known leader in authorized generics."

Clobetasol Propionate Foam 0.05% is AB-rated, therapeutically equivalent and substitutable for the brand Olux® Foam. Clobetasol Propionate Foam 0.05% is indicated for the short-term treatment of burning and itching caused by moderate to severe skin diseases of the scalp. It may also be used for psoriasis.

Olux® is a registered trademark of Stiefel Laboratories, Inc. Stiefel was acquired by GSK in July 2009.

About Prasco

Prasco provides patients, pharmacists and customers with generic options that deliver the identical brand experience. The Prasco business model encourages competition and benefits consumers through significant cost savings.

Prasco sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and mail order pharmacies. Prasco operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved facilities for Schedule II-V controlled drug products. For more information, visit www.prasco.com.

About Stiefel

Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people achieve healthy, beautiful skin. Stiefel's dedication and drive for innovation, along with its sole focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as the world leader in the skin health industry. To learn more about Stiefel, visit www.stiefel.com.

About GSK

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

SOURCE Prasco Laboratories


'/>"/>
SOURCE Prasco Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
4. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
5. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
6. Pulmo BioTech Inc. Completes Bio-Distribution Studies
7. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
8. Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
9. Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
10. RSB Spine, LLC, Announces Distribution Agreement with Paradigm BioDevices, Inc.
11. CVS Caremark Launches Distribution of $3 million in Free Seasonal Flu Shot Vouchers to the Unemployed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. ... scholarship funds for area students and operating support to UNCF-member institutions, including Miles ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to ... Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to ... drug plan (Part D) need to make changes during this period order for their ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a ... in the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. ... their education, experience, and professional associations. , One the most frequently honored ...
Breaking Medicine News(10 mins):